Compare INOD & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INOD | SRPT |
|---|---|---|
| Founded | 1988 | 1980 |
| Country | United States | United States |
| Employees | 10107 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.5B |
| IPO Year | 1996 | 2000 |
| Metric | INOD | SRPT |
|---|---|---|
| Price | $72.24 | $16.17 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 29 |
| Target Price | ★ $100.00 | $25.85 |
| AVG Volume (30 Days) | 1.6M | ★ 2.8M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.37 | N/A |
| EPS | 0.42 | ★ 2.88 |
| Revenue | $86,775,000.00 | ★ $2,198,237,000.00 |
| Revenue This Year | $38.42 | N/A |
| Revenue Next Year | $27.03 | N/A |
| P/E Ratio | $174.17 | ★ $5.56 |
| Revenue Growth | 9.84 | ★ 15.58 |
| 52 Week Low | $34.23 | $10.42 |
| 52 Week High | $125.14 | $25.32 |
| Indicator | INOD | SRPT |
|---|---|---|
| Relative Strength Index (RSI) | 36.66 | 43.75 |
| Support Level | $66.10 | $15.10 |
| Resistance Level | $77.47 | $18.16 |
| Average True Range (ATR) | 9.70 | 0.79 |
| MACD | -5.17 | 0.18 |
| Stochastic Oscillator | 3.30 | 42.57 |
Innodata Inc is a data engineering company. It is helping companies deploy and integrate AI into their operations and products and providing AI-enabled industry platforms. The Company's operations are classified in three reporting segments: Digital Data Solutions (DDS), Synodex and Agility. Key revenue is generated from DDS segment provides AI data preparation services, collecting or creating training data, annotating training data, and training AI algorithms for its customers, and AI model deployment and integration. It also provides a range of data engineering support services including data transformation, data curation, data hygiene, data consolidation, data extraction, data compliance, and master data management.
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.